Additionally, NACT became the preferred treatment approach for HER2-positive (HER2+) and triple-negative breast cancers (TNBC), even in very early breast cancer (breast mass more than 1.5 cm), according to the American Society of Clinical Oncology (ASCO) and National Comprehensive Cancer Network (NCCN) guidelines [15,16,17,18]. Here, ERBB2 is linked to triple-negative breast carcinoma.